JP2013525495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525495A5 JP2013525495A5 JP2013509223A JP2013509223A JP2013525495A5 JP 2013525495 A5 JP2013525495 A5 JP 2013525495A5 JP 2013509223 A JP2013509223 A JP 2013509223A JP 2013509223 A JP2013509223 A JP 2013509223A JP 2013525495 A5 JP2013525495 A5 JP 2013525495A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical composition
- integer
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 110
- 150000001875 compounds Chemical class 0.000 claims description 56
- 229910052742 iron Inorganic materials 0.000 claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 28
- 229910052751 metal Inorganic materials 0.000 claims description 21
- 239000002184 metal Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 206010065973 Iron Overload Diseases 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000000378 dietary effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052768 actinide Inorganic materials 0.000 claims description 5
- 150000001255 actinides Chemical class 0.000 claims description 5
- 208000005980 beta thalassemia Diseases 0.000 claims description 5
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 5
- 150000002602 lanthanoids Chemical class 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims description 2
- 201000007994 Aceruloplasminemia Diseases 0.000 claims description 2
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 2
- 108700037009 Congenital atransferrinemia Proteins 0.000 claims description 2
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims description 2
- 108700000224 Familial apoceruloplasmin deficiency Proteins 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 208000024556 Mendelian disease Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000007867 atransferrinemia Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 201000008230 cutaneous porphyria Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000037919 acquired disease Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000004885 piperazines Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 241000894007 species Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 230000009920 chelation Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- -1 6-oxo-1-cyclohexa-2,4-dienylidene Chemical group 0.000 description 2
- 241001515796 Cebinae Species 0.000 description 2
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010022979 Iron excess Diseases 0.000 description 1
- 230000010637 Metal Chelating Activity Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100001133 acute intoxication condition Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000002655 chelation therapy Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- BOFQWVMAQOTZIW-UHFFFAOYSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N1C(C=2C(=CC=CC=2)O)=NC(C=2C(=CC=CC=2)O)=N1 BOFQWVMAQOTZIW-UHFFFAOYSA-N 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229940051473 deferasirox oral suspension Drugs 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940024583 exjade Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 231100000783 metal toxicity Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33113810P | 2010-05-04 | 2010-05-04 | |
| US61/331,138 | 2010-05-04 | ||
| PCT/US2011/035211 WO2011140232A2 (en) | 2010-05-04 | 2011-05-04 | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525495A JP2013525495A (ja) | 2013-06-20 |
| JP2013525495A5 true JP2013525495A5 (enExample) | 2014-06-26 |
Family
ID=44902334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509223A Pending JP2013525495A (ja) | 2010-05-04 | 2011-05-04 | 金属キレート化剤としてのデスアザデスフェリチオシン類似体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9045440B2 (enExample) |
| EP (1) | EP2566854A4 (enExample) |
| JP (1) | JP2013525495A (enExample) |
| CN (1) | CN103038223A (enExample) |
| AU (1) | AU2011248158A1 (enExample) |
| BR (1) | BR112012028321A2 (enExample) |
| CA (1) | CA2798082A1 (enExample) |
| NZ (1) | NZ603774A (enExample) |
| WO (1) | WO2011140232A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1866296T3 (pl) | 2005-04-04 | 2017-05-31 | University Of Florida Research Foundation, Inc. | Polieterowe analogi desferritiocyny |
| CA2680592C (en) | 2007-03-15 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues and uses thereof in treating pathological conditions |
| WO2010009120A2 (en) | 2008-07-14 | 2010-01-21 | Ferrokin Biosciences, Inc. | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| CN102648189A (zh) * | 2009-07-27 | 2012-08-22 | 费罗金生物科学股份有限公司 | 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的前药 |
| EP2787994A4 (en) | 2011-12-09 | 2015-08-26 | Ferrokin Biosciences Inc | ORAL FORMULATIONS FOR TREATING METAL OVERLOAD |
| KR102111176B1 (ko) | 2011-12-16 | 2020-05-15 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 4'-데스페리티오신 유사체의 용도 |
| TW201427962A (zh) * | 2012-12-07 | 2014-07-16 | Ferrokin Biosciences Inc | 脫氮雜去鐵硫辛（ｄｅｓａｚａｄｅｓｆｅｒｒｉｔｈｉｏｃｉｎ）類似物之多晶型形式 |
| WO2014122664A1 (en) * | 2013-02-11 | 2014-08-14 | Yeda Research And Development Co. Ltd. | Lanthanide clusters and methods of use thereof |
| HK1220194A1 (zh) | 2013-03-15 | 2017-04-28 | Ferrokin Biosciences, Inc. | 去氮杂去铁硫代霉素(desazadesferrithiocin)类似物的多晶型形式 |
| EP3071201A4 (en) | 2013-11-22 | 2017-04-26 | University of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
| KR20170140306A (ko) * | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도 |
| KR102480882B1 (ko) * | 2016-08-05 | 2022-12-26 | 아브페로 파마슈티칼스, 인크. | 금속-매개 상태를 치료하기 위한 투여 요법 |
| TWI791362B (zh) | 2021-12-27 | 2023-02-01 | 財團法人工業技術研究院 | 有機金屬錯合物、包含其之觸媒組合物、以及聚烯烴的製備方法 |
| CN118561711B (zh) * | 2024-07-31 | 2024-11-22 | 爱斯特（成都）生物制药股份有限公司 | 一种制备n-[8-(2-羟基苯甲酰基)氨基]辛酸及其盐的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3002989A1 (de) * | 1980-01-29 | 1981-07-30 | Hoechst Ag, 6000 Frankfurt | Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels |
| US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
| US6251927B1 (en) * | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| US20030022923A1 (en) * | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| AT500490A1 (de) | 2001-10-16 | 2006-01-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte |
| WO2004017959A2 (en) | 2002-08-22 | 2004-03-04 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
| EP1548013A4 (en) | 2002-10-01 | 2006-07-12 | Kaneka Corp | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALPHA-SUBSTITUTED CYSTEINE OR SALT THEREOF, INTERMEDIATE THEREFOR AND PROCESS FOR PRODUCTION THEREOF |
| EP1667727B1 (en) * | 2003-09-09 | 2008-07-09 | University of Florida Research Foundation, Inc. | Polyamine-metal chelator conjugates |
| WO2005034949A1 (en) | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| JP2005289890A (ja) * | 2004-03-31 | 2005-10-20 | Mitsubishi Pharma Corp | ムスカリン性アセチルコリン受容体結合阻害剤 |
| PL1866296T3 (pl) * | 2005-04-04 | 2017-05-31 | University Of Florida Research Foundation, Inc. | Polieterowe analogi desferritiocyny |
| US20080093812A1 (en) | 2006-05-22 | 2008-04-24 | Ronald Reed | Rolling baggage wheels and method for manufacturing the same |
| US20080138440A1 (en) | 2006-11-29 | 2008-06-12 | Cormedix Inc. | Methods of diagnosing and alleviating gadolinium toxicity |
| WO2008130395A2 (en) | 2006-12-12 | 2008-10-30 | University Of Florida | Desferrithiocin analogue actinide decorporation agents |
| CA2680592C (en) * | 2007-03-15 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues and uses thereof in treating pathological conditions |
| WO2010009120A2 (en) | 2008-07-14 | 2010-01-21 | Ferrokin Biosciences, Inc. | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| CN101928281A (zh) * | 2009-06-24 | 2010-12-29 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| CN102648189A (zh) | 2009-07-27 | 2012-08-22 | 费罗金生物科学股份有限公司 | 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的前药 |
| EP2470515A4 (en) | 2009-08-25 | 2013-04-24 | Univ Florida | POLYETHER DESFERRITHIOCIN ANALOGUES AND USES THEREOF |
-
2011
- 2011-05-04 CA CA2798082A patent/CA2798082A1/en not_active Abandoned
- 2011-05-04 US US13/100,705 patent/US9045440B2/en not_active Expired - Fee Related
- 2011-05-04 CN CN2011800290386A patent/CN103038223A/zh active Pending
- 2011-05-04 US US13/695,376 patent/US20130053387A1/en not_active Abandoned
- 2011-05-04 WO PCT/US2011/035211 patent/WO2011140232A2/en not_active Ceased
- 2011-05-04 AU AU2011248158A patent/AU2011248158A1/en not_active Abandoned
- 2011-05-04 NZ NZ603774A patent/NZ603774A/en not_active IP Right Cessation
- 2011-05-04 JP JP2013509223A patent/JP2013525495A/ja active Pending
- 2011-05-04 BR BR112012028321A patent/BR112012028321A2/pt not_active IP Right Cessation
- 2011-05-04 EP EP11778269.8A patent/EP2566854A4/en not_active Withdrawn
-
2015
- 2015-05-27 US US14/722,422 patent/US20150259306A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525495A5 (enExample) | ||
| US20250375426A1 (en) | Pharmaceutical combination comprising a selective s1p1 receptor agonist | |
| JP5869469B2 (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| US20160038474A1 (en) | Compositions and methods for the modulation of hemoglobin (s) | |
| WO2015031284A1 (en) | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) | |
| Choudhry et al. | Current status of iron overload and chelation with deferasirox | |
| Italia et al. | Experimental animal model to study iron overload and iron chelation and review of other such models | |
| JP7770272B2 (ja) | 金属誘発性疾患を治療するための投与レジメン | |
| IL296586A (en) | Cyclophilin inhibitors and their uses | |
| JP7554253B2 (ja) | 輸血依存性β－サラセミア（ＴＤＴ）の治療で使用するためのフェロポーチン阻害剤 | |
| JP2015500294A (ja) | 金属過剰症を治療する経口製剤 | |
| Ceci et al. | Pharmacotherapy of iron overload in thalassaemic patients | |
| AU2020213713B2 (en) | Inositol phosphate compounds for use in increasing tissular perfusion | |
| Abdelrazik | Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience | |
| JP6179904B2 (ja) | ソラフェニブの副作用低減剤 | |
| Franchini | Recent acquisitions in the management of iron overload | |
| KR101436551B1 (ko) | 고중성지방혈증 또는 고중성지방혈증-연관 질환의 예방 또는 치료용 약학 조성물 | |
| AU2025271401A1 (en) | Dosing regimens for treating metal-mediated conditions | |
| McIntyre et al. | Deferasirox | |
| Hoffbrand et al. | Long term deferiprone chelation therapy | |
| Khan et al. | Serial serum ferritin levels for monitoring response to iron chelation therapy in patients of beta thalassemia major “Prospective cohort study” | |
| HK1176001A (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| EA048075B1 (ru) | Ингибиторы ферропортина для применения при лечении трансфузионно-зависимой бета-талассемии (tdt) | |
| Cappellini | ICL670: clinical outcome | |
| Razavi | DFT Study and Investigation of Desferrioxamine and Deferiprone in Removal of Rhodium and Iron from Biological System |